OneDigital Investment Advisors LLC Takes $560,000 Position in Moderna, Inc. $MRNA

OneDigital Investment Advisors LLC acquired a new position in Moderna, Inc. (NASDAQ:MRNA) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 7,996 shares of the company’s stock, valued at approximately $560,000.

Several other institutional investors have also recently made changes to their positions in the business. Allied Private Wealth LLC bought a new stake in Moderna during the 2nd quarter valued at approximately $30,000. Canton Hathaway LLC bought a new position in Moderna in the 1st quarter worth approximately $31,000. Assetmark Inc. boosted its stake in Moderna by 35.1% in the 1st quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after purchasing an additional 208 shares during the period. Strategic Investment Solutions Inc. IL purchased a new stake in Moderna during the 2nd quarter valued at approximately $61,000. Finally, MUFG Securities EMEA plc purchased a new stake in Moderna during the 2nd quarter valued at approximately $28,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling at Moderna

In other news, Director Noubar Afeyan sold 9,263 shares of the business’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $46.84, for a total value of $433,878.92. Following the sale, the director directly owned 3,924 shares in the company, valued at $183,800.16. The trade was a 70.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the sale, the president owned 1,483,848 shares in the company, valued at $76,225,271.76. This represents a 3.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 66,070 shares of company stock worth $3,347,299 over the last 90 days. 10.80% of the stock is owned by insiders.

Moderna Stock Down 2.3%

Shares of MRNA opened at $62.96 on Wednesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The stock has a market capitalization of $25.14 billion, a price-to-earnings ratio of -7.88 and a beta of 0.91. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $85.60. The business’s 50 day simple moving average is $62.34 and its 200-day simple moving average is $53.94.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. During the same period last year, the firm posted ($2.13) earnings per share. Moderna’s revenue for the quarter was up 2.1% compared to the same quarter last year. As a group, equities analysts expect that Moderna, Inc. will post -6.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. The Goldman Sachs Group boosted their target price on shares of Moderna from $49.00 to $67.00 and gave the stock a “neutral” rating in a report on Tuesday, July 21st. UBS Group reaffirmed an “overweight” rating on shares of Moderna in a research note on Monday, August 3rd. Piper Sandler reiterated an “overweight” rating on shares of Moderna in a report on Monday, August 3rd. Citigroup boosted their price target on shares of Moderna from $41.00 to $60.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Moderna in a report on Friday, June 12th. Three analysts have rated the stock with a Buy rating, nine have issued a Hold rating and five have issued a Sell rating to the company’s stock. According to MarketBeat, Moderna currently has an average rating of “Reduce” and a consensus price target of $42.13.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.